Moellering Robert C
Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Clin Infect Dis. 2008 Apr 1;46(7):1032-7. doi: 10.1086/529445.
During the past decade, there has been a marked increase in the prevalence of community-acquired methicillin-resistant Staphylococcus aureus infection in the United States and elsewhere. The most common such infections are those involving the skin and skin structures. Although a number of these lesions (including small furuncles and abscesses) respond well to surgical incision and drainage, oral antimicrobial agents are commonly used to treat these infections in outpatients. Unfortunately, with the exception of linezolid, none of the agents presently being used in this fashion has been subjected to rigorous clinical trial. Thus, current therapy is based largely on anecdotal evidence. For more-serious infections requiring hospitalization, parenteral antimicrobials such as vancomycin, teicoplanin, daptomycin, linezolid, and tigecycline are presently available and have demonstrated effectiveness in randomized, prospective, double-blind trials.
在过去十年中，美国及其他地区社区获得性耐甲氧西林金黄色葡萄球菌感染的患病率显著上升。此类感染最常见于皮肤及皮肤结构。尽管许多这类病变（包括小疖肿和脓肿）对手术切开引流反应良好，但门诊治疗这些感染时通常使用口服抗菌药物。不幸的是，除利奈唑胺外，目前以这种方式使用的药物均未经过严格的临床试验。因此，当前的治疗很大程度上基于轶事证据。对于需要住院治疗的更严重感染，目前可获得的肠外抗菌药物如万古霉素、替考拉宁、达托霉素、利奈唑胺和替加环素已在随机、前瞻性、双盲试验中证明有效。
